Loading quotes...

Forecast

Buy
  1
Hold
  0
Sell
  0

Discussions in the community

  • Translated from German

    History lost after ISIN change on 13.08.2026

    t torbo II in Schnack

    2 7
  • Performance der Parqet-Community

    p p III in Schnack

    3 20
  • Translated from German

    ETF Restructuring for More Monthly Cash Flow

    B BuB V in Schnack

    0 5
  • Dividenden-Dashboard fehlerhalte/fehlende Daten

    PN Parqet Nutzer V in Schnack

    0 10
  • Wie verbuche ich einen "Nachtr. Verlustverrechnung" wenn ich durch Verlust beim Verkauf Kapitalertragssteuer zurück bekomme

    u user_28c1a9 V in Schnack

    0 7

  • Fresenius sells around 13.4 million Fresenius Medical Care shares and reduces stake to about 20%

    Fresenius will immediately launch an accelerated sale process to large investors to dispose of around 13.4 million shares of Fresenius Medical Care and cut its stake from about 25% to around 20%. CEO Michael Sen says the goal is to reallocate capital to the group's growth platforms, mainly the hospital business and pharmaceuticals/medical technology. Fresenius Medical Care is under pressure due to high costs, falling profits and a leadership change; the FMC share fell after the announcement. » More on wiwo.de


  • Fresenius bets on biosimilars and WuXi deal for expansion

    Fresenius is pushing ahead with the expansion of its biopharma business: biopharma revenue grew organically almost 30% in the third quarter to €296 million, Kabi generated €2.3 billion in total, and currency‑adjusted EBIT rose to €391 million. With exclusive access to up to 37 biosimilar candidates from WuXi and the acquisition of Mabxience, the portfolio is to be expanded to as many as 66 molecules by 2030, with the aim of being among the top three providers by 2035. The group increased quarterly sales to around €5.8 billion (+5%) and reported currency‑adjusted core earnings per share of €0.72; for 2026 the company remains committed to a revenue forecast of 4–7% growth. » More on faz.net


  • Fresenius raises annual targets thanks to strong Kabi and Helios businesses

    Fresenius now expects currency-adjusted core earnings per share growth in the upper half of the 10–15% range and an EBIT margin above 11.5% for 2026. In the quarter, sales rose 6% to €5.8 billion, EBIT grew 11% to €638 million, and core earnings per share increased organically by 14%. Drivers were hospital subsidiary Helios and the Kabi division, notably the biosimilars business, which grew organically by 29%; additionally, a partnership with WuXi Biologics secures access to up to 37 further candidates. Net financial debt fell slightly to around €10.1 billion and return on invested capital (ROIC) reached 7.0%, the highest level in ten years. » More on manager-magazin.de


  • Fresenius raises forecast thanks to strong biosimilars and hospital performance

    Fresenius reports a strong third quarter: revenue rose 6% to €5.8 billion. Adjusted earnings per share, currency-adjusted, climbed to €0.72 (+14% currency-adjusted) and adjusted EBIT increased nominally by 11% to €638 million; adjusted group net income grew 15% to €403 million. CEO Michael Sen says the company is on track and now expects adjusted core earnings per share growth, currency-adjusted, to be in the upper half of the 10–15% target range. » More on wiwo.de


  • Fresenius secures access to up to 37 biosimilar candidates through partnership with WuXi Biologics

    Fresenius has agreed a ten-year development partnership with WuXi Biologics, potentially gaining access to up to 37 additional biosimilar candidates and expanding its portfolio from 29 to as many as 66 products. Target markets include originator drugs with a volume of more than €370 billion; initial focus will be on biosimilars for Polivy and Tepezza. The deal foresees milestone-based payments tied to development progress instead of large upfront fees and is intended to make the company less dependent on its dialysis and hospital businesses. CEO Michael Sen expects the first product launches in the early 2030s; Fresenius plans to fund the costs from ongoing operations and not to take on new debt. » More on n-tv.de

Historical dividends Dividends

All dividend metrics All metrics
In 2025, Fresenius has already paid €1.01 in dividends. The last payout was in May 2025.

Financials

In the last quarter, Fresenius had revenue of €5.88B and net profit of €371M
(EUR) September 2026
YoY
Revenue 5.88B 7.27%
Gross profit 1.53B 17.92%
Net profit 371M 7.85%
EBITDA 815M 2.51%

Fundamentals

Metric Value
Market capitalization
€30.2B
Number of shares
563.24M
52-week high/low
€54.35 - €35.11
Dividends No
Beta
0.77
P/E ratio
19.15
PEG ratio
0.51
P/B ratio
1.47
P/S ratio
1.27

Company profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Name
Fresenius
CEO
Michael Sen
Headquarters Bad Homburg vor der Höhe, he
Germany
Website
Sector
Health Care
Industry
Health Care Providers & Services
IPO
11/09/1998
Employees 178,394

Ticker symbols

Exchange Symbol
XETRA
FRE.DE
Pnk
FSNUF
SIX
FRE.SW
Frankfurt
FRE.F
Düsseldorf
FRE.DU
Hamburg
FRE.HM
Milan
1FRE.MI
London
0OO9.L
München
FRE.MU
Wien
FRE.VI
🍪

Parqet  uses cookies. Learn more